Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Inactivation of peroxynitrite in multiple sclerosis patients after oral administration of inosine may suggest possible approaches to therapy of the disease
Autore:
Spitsin, S; Hooper, DC; Leist, T; Streletz, LJ; Mikheeva, T; Koprowski, H;
Indirizzi:
Thomas Jefferson Univ, Biotechnol Fdn Labs, Philadelphia, PA 19107 USA Thomas Jefferson Univ Philadelphia PA USA 19107 hiladelphia, PA 19107 USA Thomas Jefferson Univ, Dept Neurol, Philadelphia, PA 19107 USA Thomas Jefferson Univ Philadelphia PA USA 19107 hiladelphia, PA 19107 USA
Titolo Testata:
MULTIPLE SCLEROSIS
fascicolo: 5, volume: 7, anno: 2001,
pagine: 313 - 319
SICI:
1352-4585(200110)7:5<313:IOPIMS>2.0.ZU;2-T
Fonte:
ISI
Lingua:
ENG
Soggetto:
EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; ANAEROBIC CYCLING PERFORMANCE; URIC-ACID; NITRIC-OXIDE; SUPPLEMENTATION; ANTIOXIDANTS; DEGRADATION; SCAVENGER; TYROSINE;
Keywords:
autoimmunity; encephalomyelitis; demyelinating diseases; multiple sclerosis; uric acid; inosine; peroxynitrite;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
22
Recensione:
Indirizzi per estratti:
Indirizzo: Koprowski, H Thomas Jefferson Univ, Biotechnol Fdn Labs, 1020 Locust St,JAH Room M-81, Philadelphia, PA 19107 USA Thomas Jefferson Univ 1020 Locust St,JAH Room M-81 Philadelphia PA USA 19107
Citazione:
S. Spitsin et al., "Inactivation of peroxynitrite in multiple sclerosis patients after oral administration of inosine may suggest possible approaches to therapy of the disease", MULT SCLER, 7(5), 2001, pp. 313-319

Abstract

Peroxynitrite has been implicated in the pathogenesis of multiple sclerosis (MS) and its animal model experimental allergic encephalomyelitis (EAE). Previously, we have shown that administration of uric acid (UA), a peroxynitrite scavenger, is therapeutic in EAE We have also shown that MS patients have lower levels of serum uric acid than healthy individuals or those withother neurological diseases. The aim of this investigation was therefore to raise serum UA levels in MS patients. Oral administration of UA foiled toincrease low serum UA levels, evidently due to its degradation by gastrointestinal bacteria. However, serum UA could be raised and maintained at elevated levels for a year and more without reported side-effects by oral administration of its precursor inosine. Three of 11 patients given inosine showed some evidence of clinical improvement and there was no sign of disease progression in the remaining patients. Gadolinium-enhanced lesions, observedin two patients before receiving inosine, could not be detected after either 10 or 15 months inosine treatment. These data provide evidence that serum UA levels can be readily manipulated and that the benefit of higher levels to individuals with MS should be studied further in greater number of patients.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/04/20 alle ore 01:17:17